Kangyuan Pharmaceutical said on the interactive platform that the company's innovative drug three-target ZX2021 and dual-target ZX2010 are undergoing phase II clinical trials. Among them, ZX2021 is carrying out a phase II clinical trial for overweight/obesity. It is designed for 24 weeks. It is expected that phase II clinical progress in weight loss and liver health improvement will be achieved in Q4 2025. ZX2010 is undergoing a phase II clinical trial for type 2 diabetes. It is designed for an 18-week trial. It is expected that key progress in reducing both sugar and weight loss will be achieved from Q4 2025 to Q1 2026.

Zhitongcaijing · 08/05/2025 10:41
Kangyuan Pharmaceutical said on the interactive platform that the company's innovative drug three-target ZX2021 and dual-target ZX2010 are undergoing phase II clinical trials. Among them, ZX2021 is carrying out a phase II clinical trial for overweight/obesity. It is designed for 24 weeks. It is expected that phase II clinical progress in weight loss and liver health improvement will be achieved in Q4 2025. ZX2010 is undergoing a phase II clinical trial for type 2 diabetes. It is designed for an 18-week trial. It is expected that key progress in reducing both sugar and weight loss will be achieved from Q4 2025 to Q1 2026.